<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01252238</url>
  </required_header>
  <id_info>
    <org_study_id>2010p001286</org_study_id>
    <nct_id>NCT01252238</nct_id>
  </id_info>
  <brief_title>Assessment of Renin Inhibition on Insulin Sensitivity, Diastolic Function and Aortic Compliance</brief_title>
  <official_title>Assessment of Renin Inhibition on Insulin Sensitivity, Diastolic Function and Aortic Compliance</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Brigham and Women's Hospital</source>
  <brief_summary>
    <textblock>
      This study is an investigation of the effect of commonly prescribed anti-hypertensive agents
      on insulin sensitivity, diastolic function and aortic compliance. The aims of the study are
      as follows:

      Specific Aim 1: To determine in insulin resistant, hypertensive subjects if renin inhibition
      for 12 weeks modifies glucose homeostasis and insulin sensitivity.

      To accomplish this specific aim, we will use three approaches: a fasting HOMA Index; and a
      three hour glucose tolerance test. Only hypertensive subjects with insulin resistance, as
      assessed by HOMA index will be enrolled in the study. Insulin resistance will be assessed
      basally and after twelve weeks of treatment with either a calcium channel blocker with
      placebo, or calcium channel blocker with a renin inhibitor, or a calcium channel blocker with
      a renin inhibitor and an angiotensin receptor antagonist.

      Specific Aim 2: To determine in insulin resistant, hypertensive subjects if renin inhibition
      for 12 weeks modifies diastolic function and aortic compliance response to dietary sodium
      intake.

      The same protocol and subjects will be used as defined in Specific Aim 1. Myocardial
      relaxation velocity (tissue Doppler imaging at the mitral annulus) and aortic compliance
      (characteristic aortic impedance) will be measured at baseline and then after acute and
      chronic renin inhibition:

        1. Acute effect of renin inhibition: Hemodynamic measurements will be obtained on both high
           and low dietary sodium intake conditions (~1 week each) before and after a single dose
           of a renin inhibitor.

        2. Chronic effect of renin inhibition: Hemodynamic measurements will be obtained at
           baseline and after 12 weeks of each of the three drug treatment arms above.

      The study lasts 12 weeks and plans to study 45 hypertensive adults over the next two years.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Study sponsor terminated study due to AE's reported with valsartan and aliskiren
  </why_stopped>
  <start_date>June 2010</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Insulin Sensitivity by HOMA at 12 Weeks</measure>
    <time_frame>12 weeks</time_frame>
    <description>The difference (change) in HOMA calculated as Baseline HOMA minus 12-week HOMA value</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Aortic Compliance</measure>
    <time_frame>12 weeks</time_frame>
    <description>Characteristic aortic imedeance, dynes x s/cm5</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Pulse Wave Velocity</measure>
    <time_frame>12 weeks</time_frame>
    <description>Measure of pulsewave velocity cm/s</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Insulin Sensitivity</condition>
  <condition>Aortic Compliance</condition>
  <condition>Diastolic Function</condition>
  <arm_group>
    <arm_group_label>Valsartan and Aliskiren</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Valsartan 150 mg and Aliskiren (150 mg followed by force titration to 300 mg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aliskiren</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Only taking Amlodipine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aliskiren</intervention_name>
    <description>Aliskiren 150 mg daily for 10 weeks, force titrated after initial 2 weeks.</description>
    <arm_group_label>Aliskiren</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Valsartan and Aliskiren</intervention_name>
    <description>Subject taking combination of valsartan and aliskiren.</description>
    <arm_group_label>Valsartan and Aliskiren</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amlodipine</intervention_name>
    <description>Taking Amlodipine as prescribed by MD for management of high blood pressure.</description>
    <arm_group_label>Placebo Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and women, 18-70 years old

          -  BMI =/&lt; 35

          -  BP: BP &gt; 145/95 on no BP medication or on 3 or less BP medications

          -  HOMA =&gt;2.5

          -  Any race

        Exclusion Criteria:

          -  4 or more BP medications

          -  Intolerance or known prior adverse history from taking the medications amlodipine,
             aliskiren or valsartan

          -  BP &gt;170/110 on screening exam

          -  Alcohol intake &gt;12 oz per week

          -  Current smoking

          -  Recreational drug use

          -  Known or suspected secondary hypertension

          -  Known history of coronary artery disease, cerebrovascular disease or congestive heart
             failure

          -  History or known kidney disease (eGFR &lt;50cc/min)

          -  Diabetes or current metformin use, or HbA1c &gt;=6.5% on screen

          -  Steroid use (oral or inhaled, chronic or within the past 6 months)

          -  Clinically significant screening lab abnormalities (See attached &quot;Screening Labs
             Acceptable Ranges&quot;)

          -  Evidence of ischemia or heart block on screening electrocardiogram (greater than type
             I-second degree heart block, left bundle branch block, or ST-T wave changes in 2 or
             more contiguous leads).

          -  Acute hospitalizations including surgery in the past 6 months

          -  Chronic use of non-steroidal anti-inflammatory or narcotic medications

          -  Women who are pregnant or nursing, or wish to become pregnant and/or who can not agree
             or tolerate two forms of birth control during the study period:

        Acceptable birth control methods for use in this study are:

          -  hormonal methods, such as birth control pills, patches, injections, vaginal ring, or
             implants

          -  barrier methods (such as a condom or diaphragm) used with a spermicide (a foam, cream,
             or gel that kills sperm)

          -  intrauterine device (IUD)

          -  abstinence (no sex)

          -  Significant concomitant medical illnesses (cancer, chronic active immunological
             conditions, etc.)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jonathan Williams, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brigham and Women's Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 1, 2010</study_first_submitted>
  <study_first_submitted_qc>December 1, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 2, 2010</study_first_posted>
  <results_first_submitted>June 24, 2013</results_first_submitted>
  <results_first_submitted_qc>June 24, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 5, 2013</results_first_posted>
  <last_update_submitted>January 18, 2018</last_update_submitted>
  <last_update_submitted_qc>January 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Brigham and Women's Hospital</investigator_affiliation>
    <investigator_full_name>Jonathan S. Williams, MD, MMSc</investigator_full_name>
    <investigator_title>Jonathan Williams, MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypersensitivity</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amlodipine</mesh_term>
    <mesh_term>Valsartan</mesh_term>
    <mesh_term>Insulin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment occurred from 8/2009 thru 12/2011 at Brigham and Women's Hospital, Boston, MA.</recruitment_details>
      <pre_assignment_details>All subjects washed out blood pressure medication for two weeks and ran in for two weeks on amlodipine 2.5-10mg titrated to BP &lt;160/90 every other day. All subjects consumed a very low salt calculated diet for one week followed by calculated high salt diet for 2 weeks prior to randomization</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Aliskiren</title>
          <description>Aliskiren : Aliskiren 150 mg daily for 10 weeks, force titrated after initial 2 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Placebo Group</title>
          <description>Only taking Amlodipine
Amlodipine : Taking Amlodipine as prescribed by MD for management of high blood pressure.</description>
        </group>
        <group group_id="P3">
          <title>Valsartan and Aliskiren</title>
          <description>Valsartan 150 mg and Aliskiren (150 mg followed by force titration to 300 mg)
Valsartan and Aliskiren : Subject taking combination of valsartan and aliskiren.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4">sponsor terminated study</participants>
                <participants group_id="P2" count="4">sponsor terminated study</participants>
                <participants group_id="P3" count="4">sponsor terminated study</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Sponsor terminated study</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Aliskiren</title>
          <description>Aliskiren : Aliskiren 150 mg daily for 10 weeks, force titrated after initial 2 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Placebo Group</title>
          <description>Only taking Amlodipine
Amlodipine : Taking Amlodipine as prescribed by MD for management of high blood pressure.</description>
        </group>
        <group group_id="B3">
          <title>Valsartan and Aliskiren</title>
          <description>Valsartan 150 mg and Aliskiren (150 mg followed by force titration to 300 mg)
Valsartan and Aliskiren : Subject taking combination of valsartan and aliskiren.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
            <count group_id="B2" value="8"/>
            <count group_id="B3" value="8"/>
            <count group_id="B4" value="24"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47" spread="12"/>
                    <measurement group_id="B2" value="51" spread="6"/>
                    <measurement group_id="B3" value="47" spread="5"/>
                    <measurement group_id="B4" value="48" spread="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Insulin Sensitivity by HOMA at 12 Weeks</title>
        <description>The difference (change) in HOMA calculated as Baseline HOMA minus 12-week HOMA value</description>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Aliskiren</title>
            <description>Aliskiren : Aliskiren 150 mg daily for 10 weeks, force titrated after initial 2 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Only taking Amlodipine
Amlodipine : Taking Amlodipine as prescribed by MD for management of high blood pressure.</description>
          </group>
          <group group_id="O3">
            <title>Valsartan and Aliskiren</title>
            <description>Valsartan 150 mg and Aliskiren (150 mg followed by force titration to 300 mg)
Valsartan and Aliskiren : Subject taking combination of valsartan and aliskiren.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Insulin Sensitivity by HOMA at 12 Weeks</title>
          <description>The difference (change) in HOMA calculated as Baseline HOMA minus 12-week HOMA value</description>
          <units>HOMA Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.7" spread="1.3"/>
                    <measurement group_id="O2" value="-0.4" spread="1.4"/>
                    <measurement group_id="O3" value="-0.5" spread="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Aortic Compliance</title>
        <description>Characteristic aortic imedeance, dynes x s/cm5</description>
        <time_frame>12 weeks</time_frame>
        <population>Comparison of Baseline vs. study drug at 12 week2</population>
        <group_list>
          <group group_id="O1">
            <title>Valsartan and Aliskiren</title>
            <description>Valsartan 150 mg and Aliskiren (150 mg followed by force titration to 300 mg)
Valsartan and Aliskiren: Subject taking combination of valsartan and aliskiren.</description>
          </group>
          <group group_id="O2">
            <title>Aliskiren</title>
            <description>Aliskiren: Aliskiren 150 mg daily for 10 weeks, force titrated after initial 2 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo Group</title>
            <description>Only taking Amlodipine
Amlodipine: Taking Amlodipine as prescribed by MD for management of high blood pressure.</description>
          </group>
        </group_list>
        <measure>
          <title>Aortic Compliance</title>
          <description>Characteristic aortic imedeance, dynes x s/cm5</description>
          <population>Comparison of Baseline vs. study drug at 12 week2</population>
          <units>dyne x sec/cm5</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="212" spread="88"/>
                    <measurement group_id="O2" value="241" spread="63"/>
                    <measurement group_id="O3" value="111" spread="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="174" spread="57"/>
                    <measurement group_id="O2" value="127" spread="0.00000"/>
                    <measurement group_id="O3" value="519" spread="499"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Pulse Wave Velocity</title>
        <description>Measure of pulsewave velocity cm/s</description>
        <time_frame>12 weeks</time_frame>
        <population>Comparison of baseline vs at 12 weeks on study drug</population>
        <group_list>
          <group group_id="O1">
            <title>Valsartan and Aliskiren</title>
            <description>Valsartan 150 mg and Aliskiren (150 mg followed by force titration to 300 mg)
Valsartan and Aliskiren: Subject taking combination of valsartan and aliskiren.</description>
          </group>
          <group group_id="O2">
            <title>Aliskiren</title>
            <description>Aliskiren: Aliskiren 150 mg daily for 10 weeks, force titrated after initial 2 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo Group</title>
            <description>Only taking Amlodipine
Amlodipine: Taking Amlodipine as prescribed by MD for management of high blood pressure.</description>
          </group>
        </group_list>
        <measure>
          <title>Pulse Wave Velocity</title>
          <description>Measure of pulsewave velocity cm/s</description>
          <population>Comparison of baseline vs at 12 weeks on study drug</population>
          <units>cm/s</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="991" spread="338"/>
                    <measurement group_id="O2" value="824" spread="106"/>
                    <measurement group_id="O3" value="1021" spread="5.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="824" spread="183"/>
                    <measurement group_id="O2" value="696" spread="0.000000"/>
                    <measurement group_id="O3" value="574" spread="584"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Aliskiren</title>
          <description>Aliskiren : Aliskiren 150 mg daily for 10 weeks, force titrated after initial 2 weeks.</description>
        </group>
        <group group_id="E2">
          <title>Placebo Group</title>
          <description>Only taking Amlodipine
Amlodipine : Taking Amlodipine as prescribed by MD for management of high blood pressure.</description>
        </group>
        <group group_id="E3">
          <title>Valsartan and Aliskiren</title>
          <description>Valsartan 150 mg and Aliskiren (150 mg followed by force titration to 300 mg)
Valsartan and Aliskiren : Subject taking combination of valsartan and aliskiren.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>No conclusions can be drawn from study due to very low sample size. The sponsor terminated the study after a separate study reported adverse events in a diabetic population who had taken both valsartan and aliskiren.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Jonathan Williams</name_or_title>
      <organization>Brigham and Women's Hospital</organization>
      <phone>617-278-0882</phone>
      <email>jwilliams5@partners.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

